drugset / Trial / NCT01606241

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01606241 ↗

Phase 1 Completed 24 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

This phase I clinical trial studies the side effects of vaccine therapy and cyclophosphamide in treating patients with stage II-III breast cancer or stage II-IV ovarian, primary peritoneal or fallopian tube cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy and cyclophosphamide may kill more tumor cells.

Timeline

Start
2012-07-24
Primary completion
2014-09-25
Completion
2018-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified — Oral
Subject Multi-epitope Folate Receptor Alpha Peptide Vaccine Vaccine — Other